TR201722323A2 - Oral pharmaceutical compositions of dabigatran - Google Patents

Oral pharmaceutical compositions of dabigatran

Info

Publication number
TR201722323A2
TR201722323A2 TR2017/22323A TR201722323A TR201722323A2 TR 201722323 A2 TR201722323 A2 TR 201722323A2 TR 2017/22323 A TR2017/22323 A TR 2017/22323A TR 201722323 A TR201722323 A TR 201722323A TR 201722323 A2 TR201722323 A2 TR 201722323A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
dabigatran
oral pharmaceutical
dabigatran etexilate
componenet
Prior art date
Application number
TR2017/22323A
Other languages
Turkish (tr)
Inventor
Palantöken Arzu
Türkyilmaz Ali̇
Gülkok Yildiz
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/22323A priority Critical patent/TR201722323A2/en
Priority to EP18877293.3A priority patent/EP3731822A1/en
Priority to PCT/TR2018/050901 priority patent/WO2019132839A1/en
Publication of TR201722323A2 publication Critical patent/TR201722323A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

The present invention relates to pharmaceutical compositions for oral administration comprising a first component comprising dabigatran etexilate free base or pharmaceutically acceptable salts of dabigatran etexilate and a second componenet comprising an organic acid.
TR2017/22323A 2017-12-27 2017-12-27 Oral pharmaceutical compositions of dabigatran TR201722323A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/22323A TR201722323A2 (en) 2017-12-27 2017-12-27 Oral pharmaceutical compositions of dabigatran
EP18877293.3A EP3731822A1 (en) 2017-12-27 2018-12-26 Oral pharmaceutical compositions of dabigatran
PCT/TR2018/050901 WO2019132839A1 (en) 2017-12-27 2018-12-26 Oral pharmaceutical compositions of dabigatran

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/22323A TR201722323A2 (en) 2017-12-27 2017-12-27 Oral pharmaceutical compositions of dabigatran

Publications (1)

Publication Number Publication Date
TR201722323A2 true TR201722323A2 (en) 2019-07-22

Family

ID=66476807

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/22323A TR201722323A2 (en) 2017-12-27 2017-12-27 Oral pharmaceutical compositions of dabigatran

Country Status (3)

Country Link
EP (1) EP3731822A1 (en)
TR (1) TR201722323A2 (en)
WO (1) WO2019132839A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112266475B (en) * 2020-11-05 2022-02-22 中国科学院长春应用化学研究所 Carbon dioxide polyester polyol, full-biodegradable carbon dioxide-based polyurethane and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
BRPI0306559B8 (en) 2002-03-07 2021-05-25 Boehringer Ingelheim Int pharmaceutical composition for oral application for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-acid ethylester mesylate 2-yl-amino]-propionic and its preparation process
DE10337697A1 (en) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
DE102005020002A1 (en) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke
SI2588090T1 (en) 2010-07-01 2017-06-30 Krka, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
JP6215239B2 (en) 2012-02-21 2017-10-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ Oral pharmaceutical composition of dabigatran etexilate
IN2013CH05441A (en) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
IN2014MU01042A (en) * 2014-03-26 2015-10-02 Cadila Healthcare Ltd
KR20170070635A (en) * 2015-12-14 2017-06-22 한미약품 주식회사 Composite capsule formulation comprising dabigatran etexilate

Also Published As

Publication number Publication date
WO2019132839A1 (en) 2019-07-04
EP3731822A1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
MX2018015709A (en) Azabenzimidazole derivatives as pi3k beta inhibitors.
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
EA201792592A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN
TR201906325T4 (en) Tetrazolone substituted dihydropyridinone MGAT2 inhibitors.
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
IN2013CH05441A (en)
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
PH12016502246A1 (en) Carboxamide derivatives
IN2014MU01042A (en)
MX2018004304A (en) Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors.
EP3500291A4 (en) Formulations for oral administration of active agents
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
IN2014MN02245A (en)
SA519410865B1 (en) Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
MX2020002078A (en) Amantadine compositions, preparations thereof, and methods of use.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
TR201722323A2 (en) Oral pharmaceutical compositions of dabigatran
WO2019004980A3 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
TR201722186A2 (en) Pharmaceutical compositions of dabigatran
IN2013MU03421A (en)
IN2014MU00859A (en)
IN2013MU03422A (en)